Andrew John Armstrong, MD

Associate Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996


Antonarakis, ES, Armstrong, AJ, Dehm, SM, and Luo, J. "Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting." Prostate cancer and prostatic diseases 19, no. 3 (September 2016): 231-241. (Review)


Sternberg, C, Armstrong, A, Pili, R, Ng, S, Huddart, R, Agarwal, N, Khvorostenko, D, Lyulko, O, Brize, A, Vogelzang, N, Delva, R, Harza, M, Thanos, A, James, N, Werbrouck, P, Bogemann, M, Hutson, T, Milecki, P, Chowdhury, S, Gallardo, E, Schwartsmann, G, Pouget, J-C, Baton, F, Nederman, T, Tuvesson, H, and Carducci, M. "Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer." August 1, 2016.

Full Text

Somarelli, JA, Schaeffer, D, Marengo, MS, Bepler, T, Rouse, D, Ware, KE, Hish, AJ, Zhao, Y, Buckley, AF, Epstein, JI, Armstrong, AJ, Virshup, DM, and Garcia-Blanco, MA. "Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways." Oncogene 35, no. 33 (August 2016): 4302-4311.


Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Evans, CP, Kim, CS, Kimura, G, Miller, K, Saad, F, Bjartell, AS, Borre, M, Mulders, P, Tammela, TL, Parli, T, Sari, S, van Os, S, Theeuwes, A, and Tombal, B. "Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study." July 28, 2016.


Somarelli, JA, Shelter, S, Jolly, MK, Wang, X, Bartholf Dewitt, S, Hish, AJ, Gilja, S, Eward, WC, Ware, KE, Levine, H, Armstrong, AJ, and Garcia-Blanco, MA. "Mesenchymal-epithelial transition in sarcomas is controlled by the combinatorial expression of miR-200s and GRHL2." Molecular and cellular biology (July 11, 2016).


Ware, KE, Somarelli, JA, Schaeffer, D, Li, J, Zhang, T, Park, S, Patierno, SR, Freedman, J, Garcia-Blanco, MA, and Armstrong, AJ. "Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer." Oncotarget (July 7, 2016).


Sonpavde, G, Pond, GR, Templeton, AJ, Fandi, A, Tombal, B, Rosenthal, M, Armstrong, AJ, and Petrylak, DP. "Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel." European urology 69, no. 6 (June 2016): 980-983.


Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 18 (June 2016): 2098-2106.


Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Molecular cancer research : MCR 14, no. 6 (June 2016): 539-547.


Halabi, S, Kelly, WK, Ma, H, Zhou, H, Solomon, NC, Fizazi, K, Tangen, CM, Rosenthal, M, Petrylak, DP, Hussain, M, Vogelzang, NJ, Thompson, IM, Chi, KN, de Bono, J, Armstrong, AJ, Eisenberger, MA, Fandi, A, Li, S, Araujo, JC, Logothetis, CJ, Quinn, DI, Morris, MJ, Higano, CS, Tannock, IF, and Small, EJ. "Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 14 (May 2016): 1652-1659.